Treatment of fibromyalgia outcomes, 9, 10 but it also can occur after an infection. Furthermore, fibromyalgia may occur with increased prevalence in people with chronic medical disorders in general. 11 Although fibromyalgia has been considered to primarily derive from pathophysiology within the central nervous system, where it is associated with disordered sensory processing, there is growing evidence to suggest that the 'fibromyalgia phenotype' may comprise multiple pathogenetic subsets, including originating, at least in part, within the peripheral nervous system. 6, 12, 13 Most cases of fibromyalgia evolve out of persistent regional pain. 14 
Diagnosis
Diagnostic criteria 15 have evolved from a recognition that fibromyalgia is a spectrum disorder, both with regards to spatial distribution of pain and symptom involvement and severity. This spectrum has been described as 'fibromyalgianess', and not as a discrete all-or-none disorder, as suggested by the original classification criteria.
Introduction
Fibromyalgia is a debilitating and often unrecognised syndrome. It affects 2% of the population with a peak incidence in middle-aged women. 1 Despite an incomplete understanding of its pathogenesis, there is increasing evidence for mechanism-based management approaches to this syndrome. 2, 3 These are likely to be more effective if introduced early, making timely diagnosis in general practice even more important.
Fibromyalgia overlaps with other functional somatic syndromes, such as irritable bowel syndrome, chronic fatigue syndrome and temporomandibular joint dysfunction. 4 While commonly co-occurring with mood and anxiety disorders, research suggests that, although functional somatic disorders are related and potentially interact with psychological conditions, they are independent. 5 The syndrome is characterised by its hallmark features of widespread somatic pain and deep tissue tenderness, which result from sensitisation of neural pain pathways. 6 There are also variable combinations of fatigue, sleep disturbance, cognitive dysfunction and psychological distress. These symptoms occur despite the absence of objective abnormalities on clinical assessment.
Pathophysiology
Fibromyalgia can develop spontaneously, 7 but is likely to represent a stereotypical, maladaptive, biological response of the body to the cumulative effects of physical or psychological stress in genetically predisposed people. 8 It is associated with psychiatric and musculoskeletal disorders, leading to poorer Although the effect sizes for interventions in fibromyalgia are generally small, these are average measures. There are subgroups of patients who will have significant benefits from particular therapeutic approaches. 3, 24 The effect sizes for nonpharmacological approaches tend to be larger than those for drugs, but combinations of drugs have only recently started to be tested. There have been some positive results, [25] [26] [27] emphasising the potential utility of a multimodal approach.
Treatment of aggravating disorders
The pain sensitisation experienced by patients with fibromyalgia is thought to result from the integrated effects of disturbed ascending facilitatory and A validated, practical, self-assessment tool based on the diagnostic criteria has been developed (Box 1) 18 to quantitate the protean symptoms of the syndrome. 19, 20 Scores above certain thresholds 20 yield reasonable specificity and sensitivity compared to the original classification criteria, 16 providing assessment by the diagnosing clinician excludes other disorders that fully explain the symptoms. 21 Examination for deep tissue tenderness, which was required by the old criteria, is now avoided. Investigations are only needed to exclude treatable comorbidities and potential differential diagnoses, such as thyroid dysfunction.
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Management
Spontaneous recovery is unusual so the aims of management are to improve symptoms, function and the quality of life. 23 There are several steps in the treatment pathway and these should be of daily physical activity can be assisted by use of an actimeter. 34 Referral to a psychologist should be considered in all patients, particularly those who are more psychologically distressed.
Pharmacological approaches
Some patients either do not tolerate or benefit from drugs. Drug therapy only has a supportive role in symptom management. All drugs should be started at low doses and cautiously increased. They should be chosen to manage the individual's predominant symptoms, with pain, sleep disturbance and psychological distress being the most amenable to drug therapy. Stop the drug if it provides no benefit.
Antidepressants
Low-dose amitriptyline has traditionally been the first-line drug for treating pain and sleep disturbance in fibromyalgia. However, the evidence supporting its use is low quality. Studies are small and short-term, but show 4.1 patients need to be treated for one to have at least 50% pain relief. However, for every 3.3 patients treated, one will have an adverse event. 35 Tolerance development and weight gain limit the use of amitriptyline, but in a small subgroup it can be very useful in the long term.
Mediators of descending inhibition in the nervous system include serotonin and noradrenaline (norepinephrine). Their concentrations are reduced in subgroups of patients with fibromyalgia, justifying a trial of a serotonin noradrenaline reuptake inhibitor.
Duloxetine at 60 mg per day has a number needed to treat for at least 50% pain relief of 8 while the number needed to harm is 18 (all neuropathic conditions pooled) in moderate-quality studies. 36 It is not approved for fibromyalgia in Australia and its benefit for other core symptoms of fibromyalgia is marginal.
Milnacipran inhibits the reuptake of serotonin and noradrenaline (norepinephrine). It has been approved in Australia for the treatment of fibromyalgia rather than depression. The recommended dose is 100 mg daily in divided doses and requires a private prescription. High-quality evidence shows it has modest efficacy. The number needed to treat for at least 30% pain relief is 11 with a number needed to harm of 14. 37 Milnacipran could have a particular role in the management of obese patients, as it appears to have no weightpromoting potential and may cause mild weight loss. 38 
Antiepileptic drugs
The concentrations of the pain facilitatory neurotransmitters glutamate and substance P in the central nervous system are elevated in fibromyalgia. They are the targets of pregabalin and gabapentin, which have potential pain modulatory, physiologicaldescending inhibitory influences, potentially at multiple levels in the central nervous system. There therefore needs to be careful clinical evaluation and management of disorders which can aggravate this disturbed neurophysiological balance (see Box 2).
Non-pharmacological approaches
The burden of living with fibromyalgia is higher than with other rheumatic disorders and higher than with most other chronic illnesses. 1, 9, 10, 28 As the medical management of fibromyalgia is often only partially successful, 2 health professionals need to give patients sustained support to become expert, active self-managers. This is the most important of all interventions to enable successful living with this debilitating multidimensional disorder. However, cognitive dysfunction related to the fibromyalgia, which is often not recognised by treating professionals, can make this process challenging.
Growing evidence suggests self-management skills training is best delivered within a supportive small group setting where education, coping skills training, and cognitive behavioural approaches can be explored. 29 Skills thereafter can perhaps be consolidated by trained peer mentors. 30 In Australia effective and sustainable models of care are yet to be developed, although internet and generic chronic pain courses can be used. 31, 32 For all health professionals, an open and patient-centred communication style is strongly recommended. 33 In general, exercise and psychoeducational approaches have the greatest evidence of efficacy among non-pharmacological therapies, 2 but they need to be tailored to the individual. Pre-exercise biomechanical assessment and subsequent exercise monitoring by a knowledgeable physical therapist are desirable for all but the mildest cases. Promotion Drugs can usefully complement an active rehabilitation program. There is some evidence for amitriptyline, duloxetine, milnacipran and pregabalin, but not all patients will benefit. Patients should be monitored for adverse events as these can limit the benefits of drug treatment.
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sleep-promoting and anxiolytic actions. High-quality evidence shows that for pregabalin the number needed to treat for at least 50% pain relief is 12 with a number needed to harm of 13. Pregabalin also has a small benefit for sleep, 39 but weight gain frequently limits its use. Although pregabalin is not listed on the Pharmaceutical Benefits Scheme (PBS) for fibromyalgia, the frequent co-occurrence of neuropathic pain meets PBS requirements.
Other drugs
There is preliminary evidence from randomised controlled trials of efficacy in subgroups treated with tramadol, 40 pramipexole 41 and memantine. 42 Pure mu-opioid receptor agonists, such as codeine, fentanyl and oxycodone, are contraindicated because of poor clinical response and increased risk of opioid-induced hyperalgesia. 40 There is no trial evidence of efficacy for paracetamol used alone and there is weak evidence that non-steroidal anti-inflammatory drugs are ineffective. 
